Investing in and building breakthrough biotech companies

Our Portfolio

Unconstrained by institution, geography or stage of company development; we have the ability to source the best life science innovation without restriction. We partner with the most ambitious entrepreneurs to build companies around game changing life science innovation.

View full portfolio

Takeda

Takeda is a global, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing better health and a brighter future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Neuroscience and Rare Diseases.

UCB

UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases in immunology or neurology. UCB is listed on Euronext Brussels (symbol: UCB).

Fosun

Fosun is a multinational company that has been listed on the main board of the Hong Kong Stock Exchange (00656.HK) since 2007. Fosun's mission is to create Customer-to-Maker ecosystems in health, happiness and wealth, providing high-quality products and services for families around the world.

Ipsen

Ipsen is a global biopharmaceutical group focused on innovation and specialty care. The group develops and commercialises innovative medicines in three key therapeutic areas - Oncology, Neuroscience and Rare Diseases.

Max Planck LDC

The Lead Discovery Center (LDC) was established in 2008 by the technology transfer organization Max Planck Innovation (MI), as a novel approach to capitalise on the potential of excellent basic research for the discovery of new therapies for diseases with high medical need. The LDC seeks to advance promising research projects into the development of novel medicines

Biomotiv

BioMotiv is a mission-driven pharmaceutical accelerator with a singular focus: Accelerating Breakthrough Discoveries into Medicines

Fred Hutch

Fred Hutchinson Cancer Research Center is dedicated to the elimination of cancer and related diseases as causes of human suffering and death. through prevention and curative treatments accessible to all patients.

Takeda

UCB

Fosun

Ipsen

Max Planck LDC

Biomotiv

Fred Hutch

Partners

Arix has developed a wide network that includes pharma companies, research accelerators and universities. Through this network, Arix is able to identify new technologies and discoveries that provide a rich pipeline of potential investments.

Team

Experienced and collaborative team, with deep industry and scientific expertise.

Meet the team

Robert Lyne

Chief Operating Officer and General Counsel

Jonathan Tobin, *PhD*

Investment Director

John Cassidy, *PhD*

Associate

Ed Rayner

Investment Director

Joe Anderson, *PhD*

Chief Executive Officer

Christian Schetter, *PhD*

Entrepreneur in Residence

Mark Chin

Investment Director

James Rawlingson

Chief Financial Officer

Investors

Public market access to revolutionary medical innovation.

Find the latest share price, presentations, events and regulatory announcements here.

ARIX BIOSCIENCE

Investing in and building tomorrow’s leading life science companies

Our Portfolio

Takeda

UCB

Fosun

Ipsen

Max Planck LDC

Biomotiv

Fred Hutch

Partners

Team

Investors

Latest News